I urge researchers to look into why side effects occur in cancer drugs and to find ways to mitigate them that doesn’t impact ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

The field of gynecological oncology has undergone significant transformations over the past few decades. Historically, the management of gynecological ...

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): a ...